Envista (NYSE:NVST – Free Report) had its price target increased by Piper Sandler from $16.00 to $17.00 in a research note published on Thursday, Benzinga reports. The brokerage currently has a neutral rating on the stock.
Several other brokerages have also recently issued reports on NVST. Bank of America cut their target price on shares of Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Evercore ISI raised their price target on shares of Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Stifel Nicolaus upped their price objective on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company began coverage on Envista in a research note on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.71.
Get Our Latest Stock Report on NVST
Envista Stock Performance
Envista (NYSE:NVST – Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The company had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. During the same quarter in the previous year, the company posted $0.43 EPS. Envista’s revenue for the quarter was down 4.8% on a year-over-year basis. Research analysts expect that Envista will post 0.7 EPS for the current year.
Insider Activity
In other Envista news, CFO Eric D. Hammes bought 24,532 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $16.33 per share, for a total transaction of $400,607.56. Following the acquisition, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Envista
Several large investors have recently made changes to their positions in the business. Tweedy Browne Co LLC purchased a new position in shares of Envista in the 1st quarter worth about $21,053,000. SG Americas Securities LLC raised its holdings in Envista by 3,271.2% in the first quarter. SG Americas Securities LLC now owns 144,522 shares of the company’s stock worth $3,090,000 after buying an additional 140,235 shares during the last quarter. M&G Plc lifted its stake in shares of Envista by 12.5% in the second quarter. M&G Plc now owns 306,253 shares of the company’s stock worth $5,206,000 after buying an additional 33,923 shares in the last quarter. Duality Advisers LP purchased a new stake in shares of Envista during the first quarter valued at approximately $1,903,000. Finally, Harbor Capital Advisors Inc. increased its position in shares of Envista by 287.4% during the second quarter. Harbor Capital Advisors Inc. now owns 169,648 shares of the company’s stock valued at $2,821,000 after acquiring an additional 125,861 shares in the last quarter.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- Canada Bond Market Holiday: How to Invest and Trade
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- How to Calculate Retirement Income: MarketBeat’s Calculator
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Options Trading – Understanding Strike Price
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.